Return to Drug Transparency Home Page:

LC-DT Home

Manufacturer Drug Transparency Guidelines, Reporting Information and Templates

Contact Us

For all report submissions or technical assistance, please use the following email:

COVID-19 Important Message

Due to the unforeseen circumstances of the COVID-19 pandemic, and the multiple challenges it has presented to normal workflow, the Department of Health and Human Services is aware that it may affect the ability to meet deadlines. Therefore, DHHS will be granting a 15-day extension to the April 1 deadline for the Essential Diabetes and Asthma Reports. All reports must be submitted by April 16, 2020. If you have already submitted your report, we thank you for your submission and are working to review them. We will be reaching out if we have any further questions or concerns.

    Drug Manufacturer Registration Template

    Reporting Instructions & Template ~ Essential Drugs Manufacturer Report

    NRS 439B.635 – Manufacturer of certain essential diabetes and asthma drugs to prepare and submit report April 1st annually.

    Reporting Instructions & Templates ~ Essential Drugs Price Increase Report

    NRS 439B.640 – Manufacturer of essential diabetes and asthma drugs that has undergone significant price increase to summit report April 1st annually.

    Reporting Instructions & Template ~ Pharmaceutical Sales Representatives Registry

    NRS 439B.660 – Manufacturer required to provide a complete list of its pharmaceutical sales representatives January 15th annually. A person who is not included on a current list submitted pursuant to subsection 1 shall not market prescription drugs on behalf of a manufacturer.

    Resources & Information